Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus | MicrobiomeTrials← Back to trialsNCT06729996
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-05-29Est. Completion: 2027-05-31
Enrollment target: 50 participants Locations- Mayo Clinic, Rochester, Minnesota, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory c…
Winston-Salem, United StatesEst. completion Jan 2027
Recurrent Acute Pancreatitis
This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute p…
Birmingham, United StatesEst. completion Sep 1, 2028